US2014303125A1PendingUtilityA1
Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency
Est. expiryApr 11, 2025(expired)· nominal 20-yr term from priority
A61P 25/30A61P 25/36A61P 25/00A61K 31/407A61K 31/137A61K 31/438A61K 31/485A61K 45/06
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency.
Claims
exact text as granted — not AI-modified1 - 22 . (canceled)
23 . A method of treating opioid dependency in a patient, said method comprising administering to said patient an effective amount of 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole in the form of a pure stereoisomer or a mixture of stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof.
24 . The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole or the physiologically acceptable salt thereof is in the form of a pure enantiomer or diastereomer.
25 . The method according to claim 23 , wherein the 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole or the physiologically acceptable salt thereof is in the form of a racemate.
26 . The method according to claim 23 , wherein the opioid dependency is heroin, morphine or methadone dependency.
27 . The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is used in combination with naloxone.
28 . The method according to claim 23 , wherein the 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of its hydrochloride, citrate, methane sulfonate or hemicitrate.
29 . The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is used in the form of the free base.
30 . The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of the non-polar diastereomer.
31 . The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of the non-polar diastereomer of the free base.
32 . The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of the non-polar diastereomer of the free base and the opioid dependency is heroin, morphine or methadone dependency.Join the waitlist — get patent alerts
Track US2014303125A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.